MX2021008800A - Barrera hematoencefalica humana in vitro. - Google Patents

Barrera hematoencefalica humana in vitro.

Info

Publication number
MX2021008800A
MX2021008800A MX2021008800A MX2021008800A MX2021008800A MX 2021008800 A MX2021008800 A MX 2021008800A MX 2021008800 A MX2021008800 A MX 2021008800A MX 2021008800 A MX2021008800 A MX 2021008800A MX 2021008800 A MX2021008800 A MX 2021008800A
Authority
MX
Mexico
Prior art keywords
brain barrier
blood brain
human blood
vitro human
ibbb
Prior art date
Application number
MX2021008800A
Other languages
English (en)
Inventor
Li- Huei Tsai
Joel Blanchard
Original Assignee
Massachusetts Inst Technology
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Massachusetts Inst Technology filed Critical Massachusetts Inst Technology
Publication of MX2021008800A publication Critical patent/MX2021008800A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/069—Vascular Endothelial cells
    • C12N5/0691—Vascular smooth muscle cells; 3D culture thereof, e.g. models of blood vessels
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/0062—General methods for three-dimensional culture
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0618—Cells of the nervous system
    • C12N5/0622—Glial cells, e.g. astrocytes, oligodendrocytes; Schwann cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5058—Neurological cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5064—Endothelial cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5082—Supracellular entities, e.g. tissue, organisms
    • G01N33/5088—Supracellular entities, e.g. tissue, organisms of vertebrates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2502/00—Coculture with; Conditioned medium produced by
    • C12N2502/28—Vascular endothelial cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2503/00—Use of cells in diagnostics
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2513/00—3D culture
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2533/00—Supports or coatings for cell culture, characterised by material
    • C12N2533/90—Substrates of biological origin, e.g. extracellular matrix, decellularised tissue

Abstract

La presente descripción proporciona, en algunas modalidades, una barrera hematoencefálica in vitro (iBBB) que tiene propiedades funcionales de BBB in vivo así como métodos para identificar los compuestos capaces de atravesar la iBBB; también se describen los compuestos capaces de atravesar la iBBB y usos terapéuticos de dichos compuestos.
MX2021008800A 2019-01-22 2020-01-22 Barrera hematoencefalica humana in vitro. MX2021008800A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962795520P 2019-01-22 2019-01-22
PCT/US2020/014572 WO2020154374A1 (en) 2019-01-22 2020-01-22 In vitro human blood brain barrier

Publications (1)

Publication Number Publication Date
MX2021008800A true MX2021008800A (es) 2021-11-12

Family

ID=69724092

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021008800A MX2021008800A (es) 2019-01-22 2020-01-22 Barrera hematoencefalica humana in vitro.

Country Status (10)

Country Link
US (1) US20220090021A1 (es)
EP (1) EP3914694A1 (es)
JP (1) JP2022523051A (es)
KR (1) KR20210131335A (es)
CN (1) CN113614222A (es)
AU (1) AU2020211961A1 (es)
CA (1) CA3127452A1 (es)
IL (1) IL285062A (es)
MX (1) MX2021008800A (es)
WO (1) WO2020154374A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114276983A (zh) * 2021-12-31 2022-04-05 广州市第一人民医院（广州消化疾病中心、广州医科大学附属市一人民医院、华南理工大学附属第二医院） 一种3d共培养4种细胞体外建立人血脑屏障模型的方法
WO2023205460A1 (en) * 2022-04-22 2023-10-26 Children’S Hospital Medical Center Vascularized brain organoids and methods of making and use

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US4485045A (en) 1981-07-06 1984-11-27 Research Corporation Synthetic phosphatidyl cholines useful in forming liposomes
US4544545A (en) 1983-06-20 1985-10-01 Trustees University Of Massachusetts Liposomes containing modified cholesterol for organ targeting
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
US5013556A (en) 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
US9932559B2 (en) * 2012-11-16 2018-04-03 The Johns Hopkins University Platform for creating an artificial blood brain barrier
US11136362B2 (en) 2016-03-10 2021-10-05 The Board Of Trustees Of The Leland Stanford Junior University Peptide modulators of specific calcineurin protein-protein interactions
EP3494213A4 (en) * 2016-08-04 2020-01-08 Wake Forest University Health Sciences MODEL FOR BLOOD BRAIN CABINETS AND METHOD FOR THE PRODUCTION AND USE THEREOF
US20180064527A1 (en) * 2016-09-07 2018-03-08 The Government Of The United States Of America, As Represented By The Secretary Of The Navy Modeling Blood-Brain Barrier in Vitro
US10451637B2 (en) * 2017-03-24 2019-10-22 The University Of British Columbia Synthetic blood vessels and uses thereof

Also Published As

Publication number Publication date
AU2020211961A1 (en) 2021-09-09
EP3914694A1 (en) 2021-12-01
JP2022523051A (ja) 2022-04-21
KR20210131335A (ko) 2021-11-02
US20220090021A1 (en) 2022-03-24
CN113614222A (zh) 2021-11-05
CA3127452A1 (en) 2020-07-30
IL285062A (en) 2021-09-30
WO2020154374A1 (en) 2020-07-30

Similar Documents

Publication Publication Date Title
MX2021013126A (es) Variantes de il-15 y usos de las mismas.
CY1118105T1 (el) Αγγειογενεση χρησιμοποιωντας πλακουντιακα βλαστικα κυτταρα
MX2019012233A (es) Anticuerpos anti-sirpa.
MX2022005291A (es) Vacunas para el tratamiento y prevencion del cancer.
MX2019001920A (es) Arn la terapia contra el cancer.
MY169165A (en) Anti-pdgfr-beta antibodies and uses thereof
MX2018009581A (es) Inmunoglobulina con fabs en tandem y sus usos.
EP1784639A4 (en) PROCESS FOR PREPARING FREEZERTED BLOOD PLATES, FLUIDIZED BLOOD PLATES, COMPOSITIONS AND USE METHOD
TW201613962A (en) Fabs-in-tandem immunoglobulin and uses thereof
EA201590085A1 (ru) Антитела анти-egfr и их применение
WO2015009726A3 (en) Medical uses of cd38 agonists
PH12018502056A1 (en) Methods of treatment of cholestatic diseases
MX352661B (es) Moduladores novedosos de benzopiran cinasa.
WO2015191934A8 (en) Blood-brain barrier (bbb) penetrating dual specific binding proteins for treating brain and neurological diseases
MX2017013142A (es) Terapia combinada para tratar cáncer.
CR20200334A (es) Compuestos, composiciones y métodos para tratar enfermedades que involucren tejidos con enfermedades ácidas o hipóxicas
CY1119432T1 (el) Αναστολεiς πυραζολυλ-γουανιδινο-f1f0-ατρασης και θεραπευτικες χρησεις αυτωn
MX2021008800A (es) Barrera hematoencefalica humana in vitro.
MX2017008823A (es) Metodos para aislamiento de plaquetas.
WO2018154118A3 (en) Aromatic compounds which enhance notch signaling, for use in therapy
MX2022001841A (es) Anticuerpos contra ilt2 y uso de los mismos.
MX2021007589A (es) Anticuerpos anti il-36 y procedimientos de uso de estos.
SG10201805646WA (en) Angiopoietin-like 4 antibodies and methods of use
MD4629B1 (ro) Metode de tratament a fibrozei şi cancerului
WO2011163512A3 (en) Cancer therapy